Why the study?
Does transcatheter aortic valve replacement improve survival and reduce complications in patients with end-stage renal disease and aortic stenosis?
Population
43 patients with end-stage renal disease and aortic stenosis, mean age 76.2 ± 11.0 years, mean STS predicted…
Design
Cohort
Follow-up
6 months
Authors
Loading...
High mortality after TAVR in ESRD warrants caution in patient selection; leaves open whether benefits exceed risks versus medical therapy.
Does transcatheter aortic valve replacement improve survival and reduce complications in patients with end-stage renal disease and aortic stenosis?
TAVR in patients with end-stage renal disease carries high mortality and complication risks, though the transfemoral approach appears to have lower operative mortality compared to non-transfemoral approaches.
Szerlip et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: